Cell & Gene Therapy

  1. SK Pharmteco Capabilities Update July 2026: Gene Therapy 8/3/2026

    Adaptive viral vector platforms pair scalable manufacturing with targeted purification. Customizing workflows ensures high vector purity and cost efficiency, accelerating clinical development.

  2. Solving Challenges For Vectors That Are Complex In Practice 7/8/2026

    Overcome adenoviral scale-up challenges with a design-to-scale manufacturing framework that optimizes cell growth, boosts vector productivity, and supports reliable clinical supply.

  3. Maximizing Efficiency In Lentiviral Vector Manufacturing 7/8/2026

    Accelerate cell and gene therapy programs with scalable lentiviral vector manufacturing, delivering high titers, exceptional purity, and reliable clinical supply from gene to clinic.

  4. Optimizing Adenoviral Production With Adaptive Process Architecture 7/8/2026

    Speed adenoviral vector development with scalable suspension processes and hybrid purification workflows that improve yield, efficiency, and clinical readiness.

  5. Advancing AAV Therapies From Concept To Commercial Supply 7/8/2026

    Accelerate gene therapy development with a scalable AAV platform delivering high yield, reproducibility, integrated analytics, and reliable clinical supply from design to production.

  6. Viral Vector Solutions That Move Your Program Forward 7/8/2026

    Optimize your viral vector program with scalable manufacturing, advanced process development, regulatory-ready workflows, and integrated fill-finish solutions to accelerate market success.

  7. A Rapid, Scalable Lentiviral Vector Purification Platform 5/15/2026

    Integrated capture and polishing reduce upstream impurities, enabling high‑capacity polishing, strong lentiviral recovery, and scalable purity for downstream in vivo applications.

  8. Accelerated Yield Optimization Of Affinity Capture 5/15/2026

    High‑throughput affinity screening shows how buffer and pH optimization can boost AAV5 recovery, enabling faster, more reliable downstream process development for challenging serotypes.

  9. Eliminating Barriers To In Vivo And Ex Vivo CAR-T Delivery 3/17/2026

    Learn how lentiviral vector processes evolve for in vivo and ex vivo CAR‑T—covering yield, purity, scalability, and shifting regulatory demands for safe, consistent systemic delivery.

  10. Revolutionizing Lentiviral Vector Manufacturing For In Vivo, Ex Vivo CAR-T Therapies 12/29/2025

    Discover how scalable, cost-effective, and high-quality lentiviral vector manufacturing can accelerate both ex vivo and emerging in vivo CAR-T therapies.